div style=”text-align: justify;”We have several firms out defending span style=”font-weight: bold;”Illumina (NASDAQ:ILMN)/span after the co pre-announced 2Q results after the close and expecting revenues to be ~$161 MM, below prior guidance range of $168-173 MM. The miss was largely attributed to weakness in the array business: 1) Slowdown in GWAS as researchers await new content; 2) Softness in Foundation funding; amp; 3) Order delays (sequencers) as researchers are uncertain about grant money.br /br /span style=”font-weight: bold;”- Deutsche Bank /spanreiterates Buy noting ST volatility does not reflect any change in fundamentals, which remain strong. ILMN est. that $10-15 MM of rev was impacted by delays in 1H’09, with some volatility expected in 3Q as well; however, stimulus benefit should make for a strong 4Q’09 (sequencing). Also, data from 1000 Genomes \should reinvigorate array growth in mid FY10 as rare variant content will drive ‘rich’ GWAS studies. Price tgt is lowered to $40 from $47.br /br /span style=”font-weight: bold;”- JP Morgan/span notes that despite the uncertainty over quarterly results, however, they maintain their long-term favorable view given the size of the genetic analysis market and strong competitive position for ILMN, which will report F2Q results on 7/21 @ 5pm ET. Maintains Overweight rating.br /br /Read-through for other life science companies . . . buy LIFE. JP Morgan does not see direct read-through for other companies in their life science tools universe, other than AFFX, which also has a GWAS business. While we expect a number of companies, incl. LIFE to be impacted by the preannouncement, they would use any pullback as a buying opportunity, in particular for LIFE, which doesn’t have a microarray business and has little near-term exposure to the GWAS slowdown. Recent commentary from management (see transcript of their call with CEO Greg Lucier last month) has also confirmed that the company has not seen a recent slowdown in academic demand.br /br /span style=”font-weight: bold;”- Morgan Stanley: 2010+ and Fundamental Story Intact, Maintaining Overweight /span… They do not believe the Illumina story is broken, with the 2010 stimulus thesis and core business fundamentals largely intact given: 1) a meaningful multi-year stimulus benefit with upside to current consensus expectations (stimulus contribution in 2010 likely conservative); 2) an intact sequencing product cycle with a longer tail than many believe; and 3) the array business is struggling through a demand gap rather than a permanent fundamental negative inflection. However, trends in genome wide association studies remain the primary risk to the stock.br /br /Maintains Overweight, lowering tgt to $38 from $42.br /br /span style=”color: rgb(255, 0, 0);”Notablecalls: /spanI think this one has a fair chance of bouncing today. $32-$33 range is my target for this one.br //divdiv class=”blogger-post-footer”img width=’1′ height=’1′ src=’https://blogger.googleusercontent.com/tracker/29297569-52520805750400622?l=notablecalls.blogspot.com’//div

Last 5 posts by Notable Calls

• Petroquest Energy (NYSE:PQ): Compelling Valuation with Near-Term Catalysts; Upgrading to Overweight - J.P. Morgan - October 29th, 2009
• 15% correction coming in SP500? - October 21st, 2009
• Boeing (NYSE:BA): Downgraded to Underweight at Morgan Stanley, target to $43 - October 20th, 2009
• Par Pharmaceuticals (NYSE:PRX): Upgraded to Overweight at Barclays; target raised to $30 - October 15th, 2009
• Wyndham Worldwide (NYSE:WYN): Upgraded to Buy at Goldman Sachs; $26 target established - October 7th, 2009